Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience
- 10 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3), e149-e160
- https://doi.org/10.1016/j.clml.2021.09.003
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphomaRadiotherapy and Oncology, 2012
- High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation RegistryTransplantation and Cellular Therapy, 2012
- Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's LymphomaThe Oncologist, 2011
- Involved Field Radiation After Autologous Stem Cell Transplant for Diffuse Large B-Cell Lymphoma in the Rituximab EraInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation VolumesJournal of Clinical Oncology, 2009
- Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and ToxicityJournal of Clinical Oncology, 2008
- A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer riskRadiation Oncology, 2007
- Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s LymphomaTransplantation and Cellular Therapy, 2006
- Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trialsAnnals of Oncology, 2006
- ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patientsBone Marrow Transplantation, 2006